Abstract:
:The impact of genetic aberrations on rituximab-based therapeutic regimens has been intensely studied in chronic lymphocytic leukemia (CLL). According to the current consensus chemoimmunotherapy consisting of rituximab and DNA-damaging drugs is not suitable for patients with TP53 defects. In our study, we focused on CLL patients with an intact TP53 gene and investigated four recurrently mutated genes in CLL, genomic aberrations by FISH, and IGHV status with the aim of analyzing their impact on progression-free survival (PFS) after front-line therapy with FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) regimens. Using next-generation sequencing, we analyzed 120 patients treated with FCR and 57 patients treated with BR at a university hospital. We used a 10% cut-off for variant allele frequency and recorded the following mutation frequencies in the pre-therapy samples: ATM 23%, SF3B1 20%, NOTCH1 19% and BIRC3 11%. The data on cytogenetic aberrations (11q22, 13q14, trisomy 12) and IGHV mutation status were also considered in PFS analyses. In univariate analyses, we observed a negative impact of BIRC3 mutations and 11q22 deletion in both regimens, while the unmutated IGHV status was associated with a significantly shorter PFS only in the FCR-treated cohort. In a multivariate analysis, only deletion 11q22 in both regimens, and the unmutated IGHV in the FCR cohort maintained an independent association with the reduced PFS. Notably, sole 11q22 deletion, without an ATM mutation on the other allele, manifested the shortest PFS of all analyzed markers. Deletion 11q22 and IGHV status predict PFS in previously untreated CLL patients.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Spunarova M,Tom N,Pavlova S,Mraz M,Brychtova Y,Doubek M,Panovska A,Skuhrova Francova H,Brzobohata A,Pospisilova S,Mayer J,Trbusek Mdoi
10.1016/j.leukres.2019.04.015subject
Has Abstractpub_date
2019-06-01 00:00:00pages
75-81eissn
0145-2126issn
1873-5835pii
S0145-2126(19)30079-7journal_volume
81pub_type
杂志文章abstract::Protein tyrosine kinase-7 (PTK7) was recently identified as a surface protein expressed on hematopoietic cells. To determine if PTK7 is a useful biomarker in clinical practice for acute leukemia immunophenotyping and detection, we examined the PTK7 expression in human bone marrow and thymic specimens. Our results show...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.07.004
更新日期:2012-11-01 00:00:00
abstract::The concurrent development of chronic myeloid (CML) or myelomonocytic (CMML) leukemia in patients with systemic mastocytosis (SM) is a well recognized phenomenon. Although the leukemia often resembles CML in morphological and in clinical terms, a Ph-Chromosome-positive variant has not been reported in SM so far. We he...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2005.04.004
更新日期:2005-10-01 00:00:00
abstract::Higher-risk myelodysplastic syndromes (MDS) are rarely curable and have a poor prognosis. We investigated the accuracy of physicians' perception of patients' health status and the patients' preferences for involvement in treatment decisions. We examined 280 newly diagnosed higher-risk elderly MDS patients paired with ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2015.05.012
更新日期:2015-08-01 00:00:00
abstract::Prospective data are needed to ascertain the impact of iron chelation therapy in patients with myelodysplastic syndromes. The present 5-year prospective registry analysis was conducted to compare clinical outcomes between chelated and nonchelated patients with lower-risk myelodysplastic syndromes and transfusional iro...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2017.01.033
更新日期:2017-05-01 00:00:00
abstract::This study was conducted to determine the frequency of the most common fusion genes in Mexican pediatric patients with acute lymphoblastic leukemia (ALL). Molecular analysis using RT-PCR was carried out in 53-blood samples: 52 patients with de novo ALL and one with relapsed ALL. The ETV6-RUNX1 fusion was found in 7 ca...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.03.021
更新日期:2008-10-01 00:00:00
abstract::In 2008 the first evidence-based Canadian consensus guideline addressing the diagnosis, monitoring and management of transfusional iron overload in patients with myelodysplastic syndromes (MDS) was published. The Canadian Consortium on MDS, comprised of hematologists from across Canada with a clinical and academic int...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2018.09.005
更新日期:2018-11-01 00:00:00
abstract::Secondary acute lymphoblastic leukemia (s-ALL) is rare and poorly defined and data regarding outcomes post-transplant are lacking. Here, we report a detailed analysis of s-ALL at our Institution. Among 211 eligible patients with ALL from 2006 to 2017, 30 (14%) were defined as s-ALL and the remaining as primary ALL (p-...
journal_title:Leukemia research
pub_type: 杂志文章,meta分析,评审
doi:10.1016/j.leukres.2018.07.024
更新日期:2018-09-01 00:00:00
abstract::Quantitative differences in HLe-1 expression were studied on normal lymphocytes and lymphoblasts of patients with acute lymphoblastic leukemia (ALL). A relationship was found between quantitative antigen expression and therapeutic outcome. Alterations in fluorescence intensity (FI) were demonstrated using quantitative...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(87)90110-x
更新日期:1987-01-01 00:00:00
abstract::We report on our experience relating to 62 patients with myelodysplastic syndrome (MDS) aged less than 50 years, seen at our Institution and conservatively treated from July 1983 to December 2000. Patients demographics and clinical features at diagnosis were analysed for their prognostic value on survival and on risk ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2005.01.003
更新日期:2005-07-01 00:00:00
abstract:BACKGROUND:Analyses suggest MDS patients with higher serum ferritin levels (SF) have inferior overall survival (OS), in one study across MDS subtypes. Multiple analyses suggest those with high SF receiving iron chelation therapy (ICT) have superior OS, but which MDS subtypes benefit from ICT remains undefined. METHODS...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2017.11.005
更新日期:2018-01-01 00:00:00
abstract::The importance of IL-18, although clearly established in solid tumors, has not been fully elucidated in human hematopoietic neoplasms. Here we examined the mRNA and protein for IL-18 in eight human hematopoietic cell lines representing different lineages and neoplasms including leukemia, lymphoma and others. Our resul...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(03)00005-5
更新日期:2003-09-01 00:00:00
abstract::In a recent phase I study, a combination of gemcitabine at 10 mg/(m(2)min) for 12 h and mitoxantrone 12 mg/m(2) daily for 3 days, achieved a complete remission (CR) in 3 of 12 (25%) patients with refractory leukemia. A pilot assessment of this regimen was conducted to determine its tolerability in patients with refrac...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章
doi:10.1016/s0145-2126(02)00171-6
更新日期:2003-04-01 00:00:00
abstract::Despite the high effectiveness of various P-glycoprotein (P-gp) modulating substances in vitro their clinical value e.g. for combination treatment of acute myelogenous leukemias (AML) remains still unclear. This might be explainable by recent findings that other factors than P-gp (e.g. the multidrug resistance associa...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(98)00192-1
更新日期:1999-05-01 00:00:00
abstract::The chemicals 6-mercaptopurine (6-MP) and methotrexate (MTX) are the cornerstones in the maintenance treatment of acute lymphoblastic leukemia. The intracellular metabolism of 6-MP to 6-thioguanosine nucleotides (TGN) via 6-thioinosine 5'-monophosphate (TIMP) is crucial for its cytotoxic effect. MTX inhibits purine de...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(92)90065-f
更新日期:1992-01-01 00:00:00
abstract::We report a unique case of de novo acute promyelocytic leukemia (APL) with cryptic 15;17 rearrangements. Cytogenetically, structural rearrangements of the 6p23 region has been reported mainly in secondary leukemia. This patient had a karyotype of 46, XY, del(6)(p23) and no additional chromosomal abnormalities. Molecul...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(99)00139-3
更新日期:2000-01-01 00:00:00
abstract::To determine the incidence of haematological malignancies in French Polynesia from 1990 to 1995, we collected cases from the local cancer registry, sanitary evacuation files and all the histopathology and clinical biology laboratories. All leukaemias, non Hodgkin's lymphomas, and multiple myelomas incidence was slight...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(98)00186-6
更新日期:1999-04-01 00:00:00
abstract::We present our first experiences with determination of minimal residual disease (MRD) based on patient specific Flt3-ITD (internal tandem duplication) mutations. We analysed MRD status of 11 AML patients in a retrospective investigation and its potential impact on the follow up of these patients. In five out of six pa...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2004.12.001
更新日期:2005-07-01 00:00:00
abstract::We report the case of an elderly patient affected by Philadelphia positive Acute Lymphoblastic Leukaemia (Ph(+) ALL) who developed meningeal leukaemia during imatinib monotherapy, despite bone marrow molecular remission. Aggressive central nervous system (CNS)-directed therapy in combination with continued imatinib tr...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2007.03.018
更新日期:2007-10-01 00:00:00
abstract::The tumor promoting agent TPA (phorbol ester; 1.6 X 10(-8)M) was used to induce the differentiation in vitro of B-chronic lymphocytic leukemia (B-CLL) cells from 14 untreated patients. The uninduced phenotype was SIg+, Mrbc+, RFT-1+, RFA-4-, FMC7-. After 72 h incubation with TPA, B-CLL cells became RFA-4+, FMC7+ and l...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(84)90005-5
更新日期:1984-01-01 00:00:00
abstract::To determine the clinical significance of the T helper 1(Th1)/T helper 2 (Th2) ratio in multiple myeloma, the intracellular IFN-gamma and IL-4 were analyzed by flow cytometry in 56 patients with multiple myeloma. The mean Th1/Th2 ratio of cases in the initial diagnosis phase and the refractory phase were higher than t...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2004.06.003
更新日期:2005-02-01 00:00:00
abstract::3-Aminobenzamide, a general inhibitor of poly(ADP-ribose)polymerase, potentiated the triamcinolone acetonide-mediated growth inhibition and lysis of the glucocorticoid-sensitive CEM-C7 human leukemic cell line. This potentiation was dose-dependent with maximal response being detected at 3 mM 3-aminobenzamide, and was ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(90)90181-8
更新日期:1990-01-01 00:00:00
abstract::With the application of adequately sensitive tests, it is now becoming evident that more than 90% of patients with conventionally-defined polycythemia vera (PV) carry the somatic JAK2V617F mutation in their granulocytes. However, the specific mutation is also found in other classic and atypical myeloproliferative diso...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2006.01.004
更新日期:2006-06-01 00:00:00
abstract::The process of B-cell development is characterized by the activation of the unfolded protein response. Under certain circumstances, the unfolded protein response can be manipulated in a cell death-inducing way. Therefore, tackling the unfolded protein response might be an attractive strategy in the treatment of diffus...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.08.017
更新日期:2013-01-01 00:00:00
abstract::To examine the relationship between viability of acute myelogenous leukemia (AML) blasts in liquid suspension culture and the occurrence of myeloid maturation in culture, total and differential cell counts and viability as determined by trypan blue dye exclusion were followed over 21 days of culture. A significant pos...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(88)90098-7
更新日期:1988-01-01 00:00:00
abstract::3q26.2/EVI1 rearrangements resulting in EVI1 overexpression play an important role in leukemogenesis and are associated with treatment resistance and a poorer prognosis in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia and BCR-ABL negative myeloproliferative neoplasms. In this...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2017.12.004
更新日期:2018-02-01 00:00:00
abstract::Bone marrow cells from 9 patients with acute myeloid leukemia and 1 patient with a blast crisis of chronic myeloid leukemia were cultured to determine their ability to be induced to differentiate by different chemotherapeutic compounds. Five of these 10 patients showed differentiation to granulocytic and/or monocytic ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(85)90087-6
更新日期:1985-01-01 00:00:00
abstract::Imatinib is a highly effective drug for the treatment of chronic myeloid leukemia (CML) that targets the BCR-ABL kinase. However, a number of patients have CML that is resistant to Imatinib treatment. In this report, we developed AGM130 as a potential therapeutic drug for Imatinib-resistant CML treatment. The AGM130 c...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.12.017
更新日期:2013-04-01 00:00:00
abstract::Screening for loss of heterozygosity (LOH) of the panel of 18 highly polymorphic microsatellite markers, especially from the region 11p15, was carried out on 154 samples from 26 patients with acute myeloid leukemia and eight with myelodysplastic syndromes (MDS). LOH was detected at the majority (72%) of the loci teste...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(00)00086-2
更新日期:2001-01-01 00:00:00
abstract::Vascular endothelial growth factor (VEGF) is pathognomonically elevated in patients with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) syndrome. However, its source of overproduction is unclear. As clinical improvement is almost always associated with VEGF reduction after...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2016.09.017
更新日期:2016-11-01 00:00:00
abstract::Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristin...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2015.08.016
更新日期:2015-08-29 00:00:00